YOU ARE HERE:
New drugs news
page  of 14
 
Headline
Date
  New 75mg darunavir tablet approved by FDA for use by HIV-positive children
06.01.09
  Enhanced Trofile assay better at identifying HIV tropisms, only slight impact on virologic outcomes
31.10.08
  Darunavir European license extended to all treatment-experienced
30.10.08
  Once-daily darunavir/ritonavir may be an option for some treatment-experienced patients
30.10.08
  Vicriviroc: long-term safety concerns over cancers dispelled
28.10.08
  Raltegravir resistance patterns becoming clearer
28.10.08
  Bevirimat: good results at 400 mg liquid dose, but formulation problems persist
27.10.08
  Darunavir effective and tolerable in treatment-experienced children and adolescents at 48 weeks
27.10.08
  No significant differences between elvucitabine and 3TC at 48 weeks
27.10.08
  Raltegravir non-inferior to efavirenz: 48 week, phase III results
27.10.08
  Once-daily darunavir (Prezista) approved for first-line use in United States
22.10.08
  Maraviroc fails to make economic case for use by NHS in Scotland
17.10.08
  New maturation inhibitor ready for trials in HIV-positive patients
22.09.08
  Herpes drug has direct anti-HIV effect, could offer cheap addition to antiretroviral therapy for developing world
11.09.08
  Brazil rejects tenofovir patent
05.09.08
  Etravirine (Intelence) approved in Europe for treatment-experienced patients
02.09.08
  Raltegravir may cause temporary worsening of pre-existing depression
02.09.08
  Next generation first-line NNRTI, rilpivirine (TMC278) potent; lowest dose better-tolerated than efavirenz at 96 weeks
19.08.08
  Heat-stable ritonavir tablet equivalent to soft gel capsule; may be approved next year
15.08.08
  Two new NNRTIs look promising in early clinical trials
08.08.08

page  of 14